Comparative Pharmacology
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus MOXIFLOXACIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus MOXIFLOXACIN HYDROCHLORIDE.
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER vs MOXIFLOXACIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
400 mg intravenously every 8-12 hours over 60 minutes.
400 mg orally or intravenously once daily for most indications; duration varies by indication.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-7 hours) in patients with normal renal function; extends to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 12-14 hours in healthy adults, allowing once-daily dosing. This is extended in severe renal impairment (creatinine clearance <30 mL/min) and in the elderly.
Renal excretion of unchanged drug accounts for approximately 50% of elimination, with 15% as metabolites; biliary/fecal excretion contributes about 20-35%.
Approximately 20% of a dose is excreted unchanged in urine, with about 25% recovered as a glucuronide conjugate (M1) and a sulfate conjugate (M2). Biliary/fecal excretion accounts for about 55% of the dose, with a portion undergoing enterohepatic recirculation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic